Neoadjuvant Envafolimab in Resectable and Locally Advanced MSI-H/dMMR Rectal Cancer

Neoadjuvant Envafolimab in Resectable and Locally Advanced MSI-H/dMMR Rectal Cancer: a Single-arm, Prospective Trial

This is a single center, prospective, single arm clinical trial to evaluate the efficacy and safety of Envafolimab as a neoadjuvant therapy for resectable and locally advanced dMMR or MSI-H rectal cancer.

Study Overview

• Status: Not yet recruiting
• Conditions: Locally Advanced Rectal Carcinoma; MSI-High
• Intervention / Treatment: Drug: Envafolimab

• Study Type: Observational
• Enrollment (Anticipated): 38

Contacts and Locations

• Study Contact: Name: Yaqi Li, PhD; Phone Number: +8615902194450; Email: yaqili702@hotmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 79 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Resectable locally advanced dMMR or MSI-H rectal cancer.

Description

Inclusion Criteria:

1. Subjects volunteer to join the study and could complete the signing of the informed consent form, and had good compliance;
2. Age ≥ 18 years old and<80 years old (when signing the informed consent form);
3. ECOG score 0-1;
4. Resectable rectal cancer was confirmed by pathological diagnosis (pathology/cytology) and imaging;
5. The clinical TNM stage is T3-4N0M0 or TanyN+M0;
6. The distance from the lower edge of the tumor to the lower edge of the anus is ≤ 10cm;
7. Patients who need routine neoadjuvant therapy after evaluation;
8. dMMR or MSI-H was detected by immunohistochemistry/PCR;
9. Patients did not received immunotherapy, chemotherapy, targeted therapy or radiotherapy for rectal cancer in the past;
10. The expected life span exceeds 3 months;
11. It has measurable lesions (according to iRECIST standard, the long diameter of CT scan for non lymph node lesions is ≥ 10 mm, and the short diameter of CT scan for lymph node lesions is ≥ 15 mm);

12. The function of main organs is normal, they should meet the following standards:

    1. Blood routine examination: Absolute Neutrophil Count (ANC) 1.5 × 109/L, Platelet (PLT) ≥ 70 × 109/L, Hemoglobin (HGB) ≥ 90 g/L;
    2. Liver function: total bilirubin (TBIL) ≤ 1.5 × Upper Limit of Normal Value (ULN); Alanine Aminotransferase (ALT) and Aspartate Transferase (AST) ≤ 3 × ULN; Serum albumin ≥ 28 g/L; Alkaline phosphatase (ALP) ≤ 5 × ULN; After routine liver protection treatment, it meets the above criteria, and can be stable for at least 1 week. After evaluation by the researcher, it can be included in the group;
    3. Renal function: serum creatinine (Cr) ≤ 1.5 × ULN, or creatinine clearance ≥ 50 mL/mi (using the standard Cockcroft Gault formula);
    4. Coagulation function: International Normalized Ratio (INR) ≤ 1.5/PT ≤ 1.5 × ULN，aPTT≤1.5 × ULN; If the subject is receiving anticoagulation treatment, PT and INR should be within the scope of anticoagulation drugs.
    5. Thyroid function: normal thyroid function, defined as thyroid stimulating hormone (TSH) within the normal range. If the baseline TSH is beyond the normal range, the subjects whose total T3 (or FT3) and FT4 are within the normal range can also be included in the group;
13. Female patients must be non pregnant and non lactating, and need to use a medically approved contraceptive measure (such as intrauterine device, contraceptive pill or condom) during the study treatment period and at least 120 days after the end of the study. During this period, it is not allowed to donate eggs to others or freeze them for fertilization and reproduction.

Exclusion Criteria:

1. Patients with active autoimmune diseases or autoimmune diseases that may recur are as follows, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism, and those who have previously undergone thyroid surgery cannot be included; Subjects who suffer from vitiligo or asthma in childhood has completely alleviated, and do not need any intervention after adulthood can be included; Asthma requiring medical intervention with bronchodilators was excluded;

2. Subjects with any severe and/or uncontrollable disease. include:

   1. Poor blood pressure control (systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg);
   2. Suffering from ≥ grade 2 myocardial ischemia or myocardial infarction, arrhythmia (QTc ≥ 470ms) and ≥ grade 2 congestive heart failure (NYHA classification);
   3. Active or uncontrolled serious infection (≥ CTCAE level 2 infection) requiring systemic anti bacterial, anti fungal or anti-virus treatment, including tuberculosis infection. Active hepatitis (transaminase does not meet the inclusion criteria, hepatitis B reference: HBV DNA ≥ 2000 IU/ml or ≥ 104 copies/ml; hepatitis C reference: HCV RNA ≥ 2000 IU/ml or ≥ 104 copies/ml; after nucleotide antiviral treatment, it is lower than the above criteria, it can be included in the group); Chronic hepatitis B virus carriers, HBV DNA<2000 IU/ml, must receive antiviral treatment at the same time during the trial to be included in the group;
   4. Renal failure requiring hemodialysis or peritoneal dialysis;
   5. Have a history of immunodeficiency, including HIV positive or other acquired or congenital immunodeficiency diseases, or have a history of organ transplantation;
3. Poor control of diabetes (fasting blood glucose [FBG]>10mmol/L);
4. Those who received major surgical treatment, open biopsy or obvious traumatic injury within 28 days before the start of the study treatment; Or there is a wound or fracture that has not been cured for a long time;
5. Serious arteriovenous thrombotic events occurred within 6 months before the study treatment, such as cerebrovascular accident (including temporary ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism;
6. Those who have a history of abuse of psychotropic substances and are unable to quit or have mental disorders;

7. Tumor related symptoms and treatment:

   1. Within 3 weeks before the start of the study treatment, he had received surgery, chemotherapy, small molecule targeted therapy, radiotherapy or other anti-tumor therapy (washout period is calculated from the end time of the last treatment).
   2. Within 2 weeks before the start of the study, those who have received the treatment of Chinese patent drugs with anti-tumor indications specified in the NMPA approved drug manual (including compound cantharis capsule, Kangai injection, Kanglaite capsule/injection, Aidi injection, Brucea javanica oil injection/capsule, Xiaoaiping tablet/injection, cinobufagin capsule, etc.);
   3. Uncontrolled pleural effusion, pericardial effusion or ascites that still need repeated drainage (judged by the investigator);

8. Study treatment related:

   1. The history of live attenuated vaccine vaccination within 14 days before the start of the study treatment or the plan for live attenuated vaccine vaccination during the study period;
   2. Severe hypersensitivity reaction occurred after using monoclonal antibody;
   3. Active autoimmune diseases requiring systemic treatment (such as the use of disease relieving drugs, corticosteroids or immunosuppressants) occurred within 2 years before the start of the study treatment, except for substitution therapy (such as thyroxine, insulin or physiological corticosteroids for adrenal or pituitary insufficiency);
   4. Diagnosed as immune deficiency or being treated with systemic glucocorticoid or any other form of immunosuppressive therapy. (dosage>10mg/day prednisone or other effective hormones), and continue to use within 2 weeks after the first administration;
   5. Have a history of active tuberculosis;
9. Those who are participating in or have participated in other clinical researches within 4 weeks before the start of the study;
10. Have a history of severe allergy;
11. Known allergy to the active ingredient or excipient of Envafolimab;
12. According to the judgment of the investigator, there are concomitant diseases that seriously endanger the safety of the subject or affect the completion of the study, or subjects who believe that there are other reasons that are not suitable for inclusion.

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Only
• Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
cCR and pCR rates	Complete clinical response rate (cCR) after neoadjuvant therapy or complete pathological response rate (pCR) of patients undergoing surgery	1-year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objective response rate (ORR)		1-year
local regrowth rate after cCR		3-year
Tumor regression grade (TRG)	Surgical excision specimens are taken every 1 cm, and the sections are given to at least 2 pathologists for independent scoring	1-year
3-year relapse-free survival	relapse-free survival refers to the period of time between the date of surgery and the day of the patient's tumor recurrence or death (earliest occurrence).	3-year
3-year overall survival	For patients who still survive when the final analysis takes place, the date of the last 1 contact will be recorded.	3-year
Patients' quality of life	The European Organization for Research and Treatment (EORTC)-QLQ-C30 HRQL questionnaire was assessed with repeated measures at regular intervals postoperatively at months 3, 6, 9, 12, 18, and 24	3-month, 6-month, 9-month, 12-month, 18-month, 24-month
Acute toxicity associated with Envafolimab	According to the NCI CTCAE v5.0 assessment, the proportion of patients with treatment-related acute toxicity developed from the beginning of treatment to 90 days after the end of Envafolimab	from the beginning of treatment to 90 days after the end of Envafolimab

Collaborators and Investigators

• Sponsor: Fudan University
• Investigators: Principal Investigator: Xinxiang Li, MD, Fudan University

Study record dates

Study Major Dates

• Study Start (Anticipated): January 1, 2023
• Primary Completion (Anticipated): June 1, 2023
• Study Completion (Anticipated): June 1, 2026

Study Registration Dates

• First Submitted: December 1, 2022
• First Submitted That Met QC Criteria: December 1, 2022
• First Posted (Actual): December 9, 2022

Study Record Updates

• Last Update Posted (Estimate): December 13, 2022
• Last Update Submitted That Met QC Criteria: December 9, 2022
• Last Verified: December 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms; Neoplasms by Site; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Intestinal Diseases; Intestinal Neoplasms; Rectal Diseases; Colorectal Neoplasms; Rectal Neoplasms
• Other Study ID Numbers: FDCRC85LXX

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No